Optibiotix Health

United Kingdom
Heslington, England, United Kingdom, YO10 5DG

Company profile

Optibiotix Health company profile

OptiBiotix develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0+
Founded
2006-07-19

Headquarters

Postal code
YO10 5DG
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
3
Total equity funding
$4.7M
Last funding
Post IPO Equity / $1M / 2025-05-23
Last equity funding
Post IPO Equity / $1M
Investors
1
Lead investors
1
Founders
1
Articles
38
Exited on
2014-08-05

Founders and investors

Founders

Stephen O' Hara

Lead investors

Graham Myers

Investors

Graham Myers